Sugi Predict

Sugi Predict / Compounds / SCHEMBL3515045

SCHEMBL3515045

SCHEMBL3515045

N[C@@H](CCSC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O)C(=O)O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DOT1L Q8TEK3 13/20 0.83
▸ DNMT3B Q9UBC3 6/20 0.83
▸ DNMT1 P26358 5/20 0.83
▸ CARM1 Q86X55 2/20 0.83
▸ EHMT2 Q96KQ7 2/20 0.83
▸ PRMT1 Q99873 2/20 0.83
▸ TRDMT1 O14717 1/20 0.83
▸ PRMT5 O14744 1/20 0.83
▸ SUV39H1 O43463 1/20 0.83
▸ PRMT3 O60678 1/20 0.83
▸ INMT O95050 1/20 0.83
▸ NSD2 O96028 1/20 0.83
▸ PNMT P11086 1/20 0.83
▸ NNMT P40261 1/20 0.83
▸ HNMT P50135 1/20 0.83
▸ WDR5 P61964 1/20 0.83
▸ KMT2A Q03164 1/20 0.83
▸ SETDB1 Q15047 1/20 0.83
▸ RBBP5 Q15291 1/20 0.83
▸ EZH2 Q15910 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27092968 1.00 DOT1L (0.83) DOT1LDNMT3BDNMT1CARM1EHMT2
SCHEMBL27092964 1.00 DOT1L (0.83) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL17316165 0.91 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL12378912 0.91 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL17087726 0.91 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL13073142 0.91 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL13033864 0.91 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL18826562 0.91 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL21160481 0.91 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2
S-Adenosylhomocysteine SCHEMBL14434697 0.91 DOT1L (1.00) DOT1LDNMT3BDNMT1CARM1EHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4324928-A1 SYNTHETIC REAGENTS FOR ENZYME-CATALYSED ALKYLATION Universität Basel (CH) 2024-02-21 — — EP claimed
US-20230220443-A1 CHARACTERIZATION OF S-ADENOSYL-L-METHIONINE-CONSUMING ENZYMES WITH 1-STEP EZ-MTASE: A UNIVERSAL COUPLED-ASSAY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-13 — — US claimed
WO-2018156464-A1 CHARACTERIZATION OF S-ADENOSYL-L-METHIONINE-CONSUMING ENZYMES WITH 1-STEP EZ-MTASE: A UNIVERSAL COUPLED-ASSAY ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2018-08-30 — — WO claimed
CN-121780501-A Homocysteine hydrolase preservation solution and detection kit containing same 深圳泰乐德医疗有限公司 2026-04-03 — — CN disclosed
EP-4324928-A1 SYNTHETIC REAGENTS FOR ENZYME-CATALYSED ALKYLATION Universität Basel (CH) 2024-02-21 — — EP disclosed
US-20230220443-A1 CHARACTERIZATION OF S-ADENOSYL-L-METHIONINE-CONSUMING ENZYMES WITH 1-STEP EZ-MTASE: A UNIVERSAL COUPLED-ASSAY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-13 — — US disclosed
US-20200239921-A1 CHEMOENZYMATIC SYNTHESIS OF S-NUCLEOSYL AMINO ACIDS (SNA), ANALOGS OF S-ADENOSYL-L-METHIONINE AND S-ADENOSYL-L- HOMOCYSTEINE AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2020-07-30 — — US disclosed
WO-2018156464-A1 CHARACTERIZATION OF S-ADENOSYL-L-METHIONINE-CONSUMING ENZYMES WITH 1-STEP EZ-MTASE: A UNIVERSAL COUPLED-ASSAY ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2018-08-30 — — WO disclosed
US-9522159-B2 Treatment and prevention of P. aeruginosa infections using coformycin analogs ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2016-12-20 — — US disclosed
US-20150231165-A1 TREATMENT AND PREVENTION OF P. AERUGINOSA INFECTIONS USING COFORMYCIN ANALOGS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2015-08-20 — — US disclosed
WO-2014043046-A1 TREATMENT AND PREVENTION OF P. AERUGINOSA INFECTIONS USING COFORMYCIN ANALOGS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2014-03-20 — — WO disclosed
US-20100291605-A1 ASSAYS FOR S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-11-18 — — US disclosed
WO-2007087541-A2 ASSAYS FOR S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 2007-08-02 — — WO disclosed
US-4011221-A TREATING TISSUE LESIONS AND ULCERS FUNAI PHARMACEUTICAL INDUSTRIES, LTD. (JA) 1977-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239921-A1 CHEMOENZYMATIC SYNTHESIS OF S-NUCLEOSYL AMINO ACIDS (SNA), ANALOGS OF S-ADENOSYL-L-METHIONINE AND S-ADENOSYL-L- HOMOCYSTEINE AND USES THEREOF SHMT1, BHMT2, AHCY DOT1L 1010/4885DNMT3B 402/4885DNMT1 155/4885
US-20150231165-A1 TREATMENT AND PREVENTION OF P. AERUGINOSA INFECTIONS USING COFORMYCIN ANALOGS MTAP, DCTD, ADA DOT1L 2749/4885DNMT3B 435/4885DNMT1 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.